A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2002
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2446234A1 Alpha-2-adrenergic agonist/fatty acid compositions
11/14/2002	CA2446161A1 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
11/14/2002	CA2445982A1 Sperm-specific cation channel, and uses therefor
11/14/2002	CA2445679A1 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	CA2445634A1 Acne treatment comprising lipoxygenase inhibitors
11/14/2002	CA2445504A1 Methods of treating hyperlipidemia
11/14/2002	CA2445502A1 Method and compositions for treating migraines
11/14/2002	CA2445271A1 Use of castanospermine esters to treat flaviviridae-related diseases
11/14/2002	CA2445157A1 Eyestrain model, method of constructing the same, evaluation method with the use of the model and drugs screened by using the evaluation method
11/14/2002	CA2445065A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	CA2444013A1 Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
11/14/2002	CA2442969A1 Methods for selective immunomodulation using pimecrolimus
11/14/2002	CA2435142A1 Kinases and phosphatases
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1256360A1 Hypertonic medicament especially for use in fluid therapy
11/13/2002	EP1256354A1 Methods for treating cancer
11/13/2002	EP1256345A1 Combination therapy for treatment of psychoses
11/13/2002	EP1256283A2 Phytopharmaceutical food products
11/13/2002	EP1255870A2 5-hydroxytryptamine transporter gene polymorphisms
11/13/2002	EP1255854A2 Interaction of nmda receptor with protein tyrosine phosphatase
11/13/2002	EP1255853A2 Methods of protein destabilization and uses thereof
11/13/2002	EP1255850A1 AMPLIFICATION OF $i(CYP24) AND USES THEREOF
11/13/2002	EP1255845A2 Modified cytokines for use in cancer therapy
11/13/2002	EP1255842A1 Larynx carcinoma-associated protein larcap-1
11/13/2002	EP1255837A2 Il-17 like molecules and uses thereof
11/13/2002	EP1255831A2 Sperm specific proteins
11/13/2002	EP1255829A2 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
11/13/2002	EP1255827A2 Novel oligonucleotides and use of oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments, as depigmentation agents
11/13/2002	EP1255823A1 Slow release protein polymers
11/13/2002	EP1255821A2 Protein c derivatives
11/13/2002	EP1255819A2 Human kinases
11/13/2002	EP1255755A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
11/13/2002	EP1255725A2 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
11/13/2002	EP1255718A1 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
11/13/2002	EP1255566A2 Preparation of aqueous clear solution dosage forms with bile acids
11/13/2002	EP1255564A2 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator
11/13/2002	EP1255559A2 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease
11/13/2002	EP1255558A1 Uses of agonists and antagonists to modulate activity of tnf-related molecules
11/13/2002	EP1255556A2 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
11/13/2002	EP1255553A2 Use of trilostane and its derivatives, optionally in combination with tamoxifen or raloxifene in the treatment of estrogen-dependent cancers e.g. breast, prostate and uterus cancers
11/13/2002	EP1255552A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
11/13/2002	EP1255550A2 Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
11/13/2002	EP1255545A2 L-arginine in combination with other compounds for treating cardiovascular diseases
11/13/2002	EP1255544A1 Mucin synthesis inhibitors
11/13/2002	EP1255543A2 Use of retinoid-type compounds as antibacterial agents
11/13/2002	EP1255541A2 Pharmaceutically active aromatic guanylhydrazones
11/13/2002	EP1255540A1 Ophthalmic use of alpha adrenergic blocking agents
11/13/2002	EP1255539A1 Use of alpha 1a? adrenoceptor agonists with alpha 1b? and alpha 1d? antagonism for the treatment of stress urinary incontinence
11/13/2002	EP1255537A2 Farnesyl protein transferase inhibitors for treating breast cancer
11/13/2002	EP1113811B1 Chemokine receptor antagonist and cyclosporin in combined therapy
11/13/2002	EP1012162B1 Soluble proteins
11/13/2002	EP0977575B1 The use of alpha-methyl-p-tyrosine to inhibit melanin production in iris melanocytes
11/13/2002	EP0912515B1 1,4-di-substituted piperidines as muscarinic antagonists
11/13/2002	EP0912167B1 Granulates of hexahydropyrazine derivatives which can be administered orally
11/13/2002	EP0843557B1 Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
11/13/2002	EP0735863B1 Accelerated release composition containing bromocriptine
11/13/2002	CN1379817A Composition and methods for increasing cholesterol efflux and raising HDL using ATP binding cassettte ttansporter protein ABC1
11/13/2002	CN1379816A Human G-protein coupled receptor
11/13/2002	CN1379785A Caspase inhibitors for treatment and prevention of chemotherapy and radiation therapy induced cell death
11/13/2002	CN1379686A Composition comprising tramadol material and anticonvulsant drug
11/13/2002	CN1379685A Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta integrins
11/13/2002	CN1379678A Method for calming human beings using personal care compositions
11/13/2002	CN1379675A 24-hydroxyvitamin D, analogs and use thereof
11/13/2002	CN1379672A Highly selective norepinephrine reuptake inhibitors and methods of using same
11/13/2002	CN1379671A Treating sleep disorders using desloratadine
11/13/2002	CN1379669A Valdecoxib compositions
11/13/2002	CN1379664A Activation and protection of cytotoxic lymphocytes using reactive oxygen metabolite inhibitor
11/12/2002	US6480405 Full-wave rectifier
11/12/2002	US6479630 Human purinergic P2U receptor
11/12/2002	US6479553 Use of certain affinity NMDA antagonists as antidepressants
11/12/2002	US6479551 Treatment of migraine headache
11/12/2002	US6479548 Substituted stilbenes as glucose uptake enhancers
11/12/2002	US6479545 Formulation for menopausal women
11/12/2002	US6479540 Compositions of tocol-soluble therapeutics
11/12/2002	US6479537 Combination of the macrocyclic lactone moxidectin and an phenyl-substituted 4-cyano-3-halo-2-(trifluoromethyl)pyrrole compound.
11/12/2002	US6479523 Achieved by electrical stimulation of the vagus nerve and administration of a combination of drugs including: an acetylcholinesterase inhibitor, a beta-adrenergic receptor blocker, and a calcium channel blocker
11/12/2002	US6479513 Anticancer compound and enantiomer separation method useful for synthesizing said compound
11/12/2002	US6479512 Tyrosine kinase inhibitors
11/12/2002	US6479481 Administering an effective dose of a cns tumor-inhibiting methylol transfer agent such as: taurolidine, taurultam or a mixture thereof.
11/12/2002	US6479466 A hydroxylated stilbene that promotes dna synthesis in a virally-targeted cell such as resveratrol; a nucleoside analogue having antiviral activity such as dideoxyinosine
11/12/2002	US6479463 Used to treat an infection, an infestation, a neoplasm, or an autoimmune disease or to modulate aspects of the immune system, including modulation of th1 and th2
11/12/2002	US6479458 Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
11/12/2002	US6479270 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
11/12/2002	US6479261 Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells
11/12/2002	US6479068 Administering glutamine, vitamins a, c and e, and selenium
11/12/2002	US6479067 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
11/12/2002	US6479049 Methods and compositions for the dry powder formulation of interferons
11/12/2002	CA2271781C Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
11/12/2002	CA2246839C Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy
11/12/2002	CA2244253C Method for preventing and treating peripheral neuropathy by administering selegiline
11/12/2002	CA2204535C Molecules that home to a selected organ or tissue in vivo and methods of identifying same
11/12/2002	CA2092435C Uracil reductase inactivators
11/12/2002	CA2068083C Anti-bacterial compound
11/12/2002	CA2059558C Use of calcium antagonists for treating scars
11/12/2002	CA2055948C Use of a combination of angiotensin-converting enzyme inhibitor and calcium antagonist for the treatment of proteinuria
11/11/2002	CA2385692A1 Thiazole derivatives
11/09/2002	CA2385412A1 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
11/08/2002	WO2001082942A1 Compositions and methods for treatment of multiple myeloma
11/08/2002	CA2425954A1 Compositions and methods for treatment of multiple myeloma

1 ... 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 ... 1151